Disparities in adjuvant treatment of high-grade endometrial cancer in the Medicare population

被引:9
|
作者
Corey, Logan [1 ,2 ]
Cote, Michele L. [1 ,3 ]
Ruterbusch, Julie J. [1 ]
Vezina, Alex [4 ]
Winer, Ira [1 ,2 ]
机构
[1] Wayne State Univ, Sch Med, Dept Oncol, Detroit, MI 48201 USA
[2] Barbara Ann Karmanos Canc Inst, Dept Gynecol Oncol, Detroit, MI USA
[3] Barbara Ann Karmanos Canc Inst, Populat Sci & Dispar Res, Detroit, MI USA
[4] Womens Comprehens Care, Detroit, MI USA
基金
美国国家卫生研究院;
关键词
adjuvant Treatment; high-grade endometrial cancer; racial disparities; RACIAL DISPARITIES; POSTOPERATIVE COMPLICATIONS; SURVIVAL; WOMEN; SURGERY; CHEMOTHERAPY; EPIDEMIOLOGY; RADIOTHERAPY; HYSTERECTOMY; MULTICENTER;
D O I
10.1016/j.ajog.2021.10.031
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
BACKGROUND: Black women experience worse survival effects with high-grade endometrial cancer. Differences in adjuvant treatment have been proposed to be major contributors to this disparity. However, little is known about the differences in type or timing of adjuvant treatment as it relates to race and ethnicity in the Medicare population. OBJECTIVE: This study aimed to examine patterns of adjuvant therapy and survival for non-Hispanic Black women vs non-Hispanic White women and Hispanic women who have undergone surgery for high-grade endometrial cancer in the Medicare population. STUDY DESIGN: We used the Medicare-linked Surveillance, Epidemiology, and End Results database to identify women who underwent surgery as a primary treatment for uterine grade 3 endometrioid adenocarcinoma, carcinosarcoma, clear-cell carcinoma, or serous carcinoma between the years 2000 and 2015. Women who did not identify as White or Black race or Hispanic ethnicity were excluded. Multinomial logistic regression was used to estimate odds ratios and 95% confidence intervals for receiving a treatment delay or not receiving adjuvant treatment (compared with those who received adjuvant treatment within 12 weeks) adjusted for clinical and demographic characteristics. Overall survival was stratified by race and ethnicity, route of surgery, operative complications, and type and timing of adjuvant therapy, which were analyzed using the Kaplan-Meier method. Cox proportional-hazards regression was used to estimate the hazard ratio of death by race and ethnicity adjusted for known predictors and surgical outcomes and adjuvant therapy patterns. RESULTS: A total of 12,201 womenmet the study inclusion criteria. Non-Hispanic Black patients had a significantly worse 5-year overall survival than Hispanic and non-Hispanic White patients (30.9 months vs 51.0 months vs 53.6 months, respectively). Approximately 632 of 7282 patients (8.6%) who received adjuvant treatment experienced a treatment delay. Delay in treatment of >= 12 weeks was significantly different by race and ethnicity (P = .034), with 12% of Hispanic, 9% of non-Hispanic Black, and 8% of non-Hispanic White women experiencing a delay. After adjustment for the number of complications, age, histology (endometrioid vs nonendometroid), International Federation of Gynecology and Obstetrics stage, marital status, comorbidity count, surgical approach, lymph node dissection, and urbanrural code, Hispanic women had a 71% increased risk of treatment delay (odds ratio, 1.71; 95% confidence interval, 1.23-2.38) for all stages of disease. In the same model, non-Hispanic Black race was independently predictive of decreased use of adjuvant treatment for the International Federation of Gynecology andObstetrics stage II and higher (odds ratio, 1.32; 95% confidence interval, 1.04-1.68). Non-Hispanic Black race, number of perioperative complications, and nonendometrioid histology were predictive of worse survival in univariate models. Treatment delay was not independently predictive of worse 1- or 5-year survival at any stage. CONCLUSION: Non-Hispanic Black race was predictive of worse 5-year survival across all stages and was associated with omission of adjuvant treatment in International Federation of Gynecology and Obstetrics stage II or higher high-grade endometrial cancer. In unadjusted analyses, patients who experience treatment omission or delay experienced poorer overall survival, but these factors were not independently associated in multivariate analyses. This study suggests that race and ethnicity are independently associated with the type and timing of adjuvant treatment in patients with high-grade endometrial cancer. Further efforts to identify specific causes of barriers to care and timely treatment are imperative.
引用
收藏
页码:541.e1 / 541.e13
页数:13
相关论文
共 50 条
  • [21] High-grade endometrial stromal sarcoma following tamoxifen treatment
    Engin, Hueseyin
    [J]. GYNECOLOGIC ONCOLOGY, 2008, 108 (01) : 253 - 254
  • [22] Management and Outcomes for Elderly Women with High-Grade Endometrial Cancer
    Pepin, Kristen J.
    Rauh-Hain, J. Alejandro
    Meyer, Larissa A.
    Clemmer, Joel
    Lu, Karen H.
    Rice, Laurel W.
    Uppal, Shitanshu
    Schorge, John O.
    del Carmen, Marcela G.
    [J]. GYNECOLOGIC ONCOLOGY, 2015, 139 (03) : 587 - 587
  • [23] Robotic surgery compared with laparotomy for high-grade endometrial cancer
    Pant A.
    Schink J.
    Lurain J.
    [J]. Journal of Robotic Surgery, 2014, 8 (2) : 163 - 167
  • [24] Sentinel Lymph Node Mapping in High-Grade Endometrial Cancer
    Salman, Lina
    Cusimano, Maria C.
    Marchocki, Zibi
    Ferguson, Sarah E.
    [J]. CURRENT ONCOLOGY, 2022, 29 (02) : 1123 - 1135
  • [25] Sentinel lymph node mapping for high-grade endometrial cancer
    Collado, F. Khoury
    Soslow, R.
    Pandit-Taskar, N.
    Diaz, J.
    Murray, M.
    Chi, D.
    Barakat, R.
    Gemignani, M.
    Abu-Rustum, N.
    [J]. GYNECOLOGIC ONCOLOGY, 2010, 116 (03) : S72 - S72
  • [26] Sentinel lymph node biopsy in high-grade endometrial cancer
    Marchocki, Zibi
    Cusimano, Maria C.
    Ferguson, Sarah E.
    [J]. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2022, 226 (06) : 867 - 868
  • [27] TUMOR TREATING FIELDS: ADJUVANT TREATMENT FOR HIGH-GRADE GLIOMAS
    Anthony, Patricia
    McArdle, Stacey
    McHugh, Michele
    [J]. SEMINARS IN ONCOLOGY NURSING, 2018, 34 (05) : 454 - 464
  • [28] High-grade uterine corpus-confined endometrial cancer with lymphadenectomy: does adjuvant therapy improve survival?
    Kilic, Cigdem
    Cakir, Caner
    Yuksel, Dilek
    Durmus, Yasin
    Boran, Nurettin
    Comert, Gunsu Kimyon
    Karalok, Alper
    Boyraz, Gokhan
    Turan, Taner
    [J]. TURKISH JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2019, 16 (03) : 180 - 186
  • [29] THE IMPACT OF HISTOLOGY AND ADJUVANT THERAPY ON SURVIVAL AND RECURRENCE PATTERNS AMONG HIGH-GRADE ENDOMETRIAL CANCER WITH RETROPERITONEAL METASTASES
    McEachron, J.
    Marshall, L.
    Tran, V.
    Zhou, N.
    Kanis, M.
    Gorelick, C.
    Lee, Y.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2020, 30 : A106 - A107
  • [30] Evaluation of Survival, Recurrence Patterns and Adjuvant Therapy in Surgically Staged High-Grade Endometrial Cancer with Retroperitoneal Metastases
    McEachron, Jennifer
    Marshall, Lila
    Zhou, Nancy
    Tran, Van
    Kanis, Margaux J.
    Gorelick, Constantine
    Lee, Yi-Chun
    [J]. CANCERS, 2021, 13 (09)